Biopharma companies are expanding beyond the traditional confines of Massachusetts and California with hubs forming – most notably – in the South and Southeast.
The Home of the Life Sciences Industry
Theratechnologies’ Trogarzo for HIV, Alnylam’s Lumasiran for advanced primary hyperoxaluria, scPharmaceuticals' Furoscix for heart failure and more. Here's a look at the FDA's October calendar.
More Top Stories
- BioMarin Banks on More Robust Data in Hemophilia A Resubmission
- Moderna Bolsters Leadership with New Execs to Support Upcoming Pipe...
- Rocket Takes Off on Early Data from Danon Gene Therapy
- FDA Review: Amylyx, Sarepta, Sanofi-Regeneron and More
- Gilead Identifies ‘Kingpins’ Behind HIV Drug Counterfeit Ring (Upda...